Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Zevra Therapeutics revealed that the US Food and Drug Administration (FDA) has indicated it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review the New Drug Application (NDA) for arimoclomol. 15 July 2024
Swiss drugmaker Novartis has launched legal action against the US government, after administrators revealed the first drugs to be subject to pricing regulations mandated by the Inflation Reduction Act (IRA). 7 September 2023
Japanese pharma major Astellas Pharma revealed that it has requested that the Court dismiss the company’s lawsuit challenging the constitutionality of certain provisions of the US government’s Inflation Reduction Act (IRA). 7 September 2023
Cardiometabolic med Jardiance (empagliflozin), a blockbuster product developed by Boehringer Ingelheim and Eli Lilly, has picked up a new approval in the UK. 7 September 2023
The National Institute for Health and Care Excellence (NICE) has published Final Guidance on a new medicine for the treatment of the most common inherited heart condition in England and Wales. 6 September 2023
The UK is an attractive place to conduct life science research and development (R&D). However, we must caveat this statement with the words, ‘for now’. 6 September 2023
Cambridge, US-based Apollo Therapeutics today announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital. 6 September 2023
Marie-France Tschudin, president, innovative medicines international and chief commercial officer of Novartis, has decided to leave the Swiss pharma giant and will step down from the executive committee of Novartis. 6 September 2023
Dr Monica Shaw has joined the commercial leadership team of US pharma major Bristol Myers Squibb’s as senior vice president, major markets. 6 September 2023
The Russian segment of drug public procurements significantly declined this year, mainly as a result of a significant drop of purchases under various state programs, The Pharma Letter’s local correspondent reports. 6 September 2023
Shares of Spanish dermatology-focused drugmaker Almirall rallied yesterday, after the company revealed in a brief stock exchange filing that it is looking to expand its therapeutic range. 5 September 2023
Palforzia was going to be the keystone product in Nestle’s strategic expansion into biotech, but the Swiss food and drink giant has finally thrown in the towel. 5 September 2023
Italy’s privately-held drug developer Italfarmaco Group today revealed that its Marketing Authorization Application (MAA) for Givinostat as a potential treatment for Duchenne muscular dystrophy (DMD) has been submitted to the European Medicine Agency. 5 September 2023
Dutch specialty pharma firm Pleco Therapeutics has appointed Dr Henno Welgemoed in the newly created role of chief medical officer (CMO). 5 September 2023
Privately-held Italian drugmaker Angelini Pharma today shared positive findings from post-hoc analyses of the C017 open-label extension (OLE) study. 4 September 2023
Shares of Australian specialty pharma firm Mayne Pharma Group closed up 9.2% at A$3.68 today, after it released full-year fiscal 2023 financials, showing that reported revenues were A$183.6 million (US$118.5 million), up 17% on FY 2022. 4 September 2023
AbbVie has announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Aquipta (atogepant) for the prophylaxis of migraine in adults who have at least four migraine days per month. 4 September 2023
Since first demonstrating clinical success in the treatment of obesity, Wegovy (semaglutide) has garnered ever increasing amounts of interest from patients, providers and investors alike. 4 September 2023